leadf
logo-loader
viewLexaGene Holdings Inc.

LexaGene Holdings set to deploy its MiQLab Systems at two veterinary hospitals in US

The point-of-care technology will be available at the Veterinary Specialty Hospital of Palm Beach Gardens, Florida, and at Denver Animal Emergency in Denver, North Carolina

LexaGene Holdings Inc. -
The MiQLab-generated data will be evaluated against traditional culture and sensitivity testing that typically takes three to five days for results

LexaGene Holdings Inc (CVE:LXG) (OTCQB:LXXGF) (FRA:5XS2), the molecular diagnostics group, is set to deploy its MiQLab systems into two specialty and emergency veterinary hospitals, which will allow for rapid testing of animals.

The point-of-care technology will be available at the Veterinary Specialty Hospital (VSH) of Palm Beach Gardens, Florida, and at Denver Animal Emergency (Denver) in Denver, North Carolina.

READ: LexaGene Holdings receives purchase order for a MiQLab system from Ethos Discovery

“I am very pleased that VSH will be able to evaluate LexaGene’s MiQLab system," said Dr. Jorg Bucheler, the practice owner of VSH.

"We pride ourselves on using the very latest technology and techniques in specialty and critical care to deliver the highest level of service we can provide our patients. Having access to rapid PCR in-clinic testing will allow us to triage critical and complicated infections more effectively.”

Lexagene CEO and founder Dr Jack Regan added: "We expect these systems to demonstrate the advantage of having in-house automated rapid testing for pathogens and antibiotic resistance markers, which is expected to improve patient care and clinical outcomes.

"The feedback we receive from these industry leading practices will help us in our efforts to gain wide adoption in this market."

The MiQLab-generated data will be evaluated against traditional culture and sensitivity testing that typically takes three to five days for results.

By contrast, MiQLab provides results fast enough to allow care providers to make knowledge-based decisions for timely patient care," noted Lexagene.

The company expects to place systems for these evaluations shortly after the new year.

Contact the author at [email protected]

Quick facts: LexaGene Holdings Inc.

Price: 1.26 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $143.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

LexaGene starts program to Identify UK and South African COVID Sequences

Lexagene Holdings (CVE: LXG- OTCQB: LXXGF) CEO Jack Regan joined Steve Darling from Proactive with news the company is planning to use their patented MiQLa system to investigate novel variants of the SARS-Cov-2 which is the pathogen that causes COVID-19. Dr. Regan telling Proactive this...

2 days, 3 hours ago

2 min read